M MaxCyte® Driving the Next Generation of Cell-Based Therapies MaxCyte Corporate Presentation NASDAQ: MXCT • LSE: MXCT, MXCN February 2022 are trademarks of MaxCyte, Inc. in the U.S.A. ® ® ® ® TM © 2019 MaxCyte, Inc. All Rights Reserved info@maxcyte.com | www.maxcyte.com ir@maxcyte.com | www.maxcyte.com Disclaimer The content of this document (the "Presentation") has not been approved by an authorized person within the meaning of the Financial Services and Markets Act 2000 ("FSMA"), as amended. Reliance on ...

MaxCyte, Inc. (NASDAQ:MXCT) Q3 2021 Earnings Conference Call November 10, 2021 4:30 PM ET Company Participants Sean Menarguez - Investor Relations Douglas Doerfler - Chief Executive Officer Amanda Murphy - Chief Financial Officer Conference Call Participants Julie Simmonds - Panmure Gordon Max Masucci - Cowen & Company Evan Stampler - Stifel Matthew Larew - William Blair Vidyun Bais - BTIG Jacob Johnson - Stephens Sean Menarguez Good afternoon, everyone. My name is Sean Menarguez, and I'm an analyst on the ...

MaxCyte, Inc. (NASDAQ:MXCT) Q2 2021 Earnings Conference Call September 13, 2021 4:30 PM ET Company Participants Sean Menarguez - IR Doug Doerfler - CEO Amanda Murphy - CFO Conference Call Participants Julie Simmonds - Panmure Gordon Max Masucci - Cowen & Co. Dan Arias - Stifel Matt Larew - William Blair Mark Massaro - BTIG Jacob Johnson - Stephens, Inc. Sean Menarguez Good afternoon, everyone. Thank you all for participating in today's conference call. On the call for MaxCyte, we have Doug Doerfler, Chief E ...